NantKwest Profile

Performance

   

Odds of Distress

9%9%
Check how we calculate scores
Equity ratings for NantKwest are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting June 21, 2019 and ending today September 19, 2019. Click here to learn more.

NantKwest Summary

NantKwest (NK) is traded on BATS Exchange in USA. It is located in 3530 John Hopkins Court and employs 151 people. NantKwest is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with market capitalization of 127.8M. NantKwest is active under Healthcare sector as part of Biotechnology industry. The entity has 98.31M outstanding shares of which 3.39M shares are now sold short in the market by investors with about 15.07 days to cover all shorted shares. NK reports about 84.05M in cash with (61.51M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86.
Check NantKwest Probability Of Bankruptcy

Ownership Allocation (%)

NantKwest Target Price Odds Analysis

Odds Below 1.3HorizonTargetOdds Above 1.3
78.16%30 days 1.30 21.71%
Based on normal probability distribution, the odds of NantKwest to move above current price in 30 days from now is about 21.71% (This NantKwest probability density function shows the probability of NantKwest Stock to fall within a particular range of prices over 30 days) .

NantKwest Top Holders

NantKwest Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

NantKwest Key Fundamentals

NantKwest Against Markets

NantKwest Vital Trading Data

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California. NantKwest operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 151 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NantKwest SEC Filings
NantKwest SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameNantKwest
President CEO, Board MemberBarry SimonView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCalifornia U.S.A
Business Address3530 John Hopkins Court
ExchangeBATS Exchange
CIK Number0001326110
CUSIP63016Q102
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.nantkwest.com
Phone858 633 0300
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestAugust 15, 2019

NantKwest Corporate Directors

Cheryl Cohen Director
Richard Kusserow Independent Director
Michael Blaszyk Independent Director
Please see also Stocks Correlation. Please also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Search macroaxis.com